Impact of Solidago virgaurea Extract on Biofilm Formation for ESBL- Pseudomonas aeruginosa: An In Vitro Model Study
- PMID: 37895854
- PMCID: PMC10609828
- DOI: 10.3390/ph16101383
Impact of Solidago virgaurea Extract on Biofilm Formation for ESBL- Pseudomonas aeruginosa: An In Vitro Model Study
Abstract
The increasing disparity between antimicrobial resistance (AMR) and the development of new antimicrobials continues to pose a significant global health concern. However, plant extracts have shown promise in combating this issue either through their inherent antimicrobial activity or by serving as potential reservoirs of effective antimicrobial compounds. These compounds have the ability to target pathogenic biofilms and inhibit the production of extended-spectrum β -lactamases (ESBLs). However, there is limited research available on the antibacterial properties of goldenrod extract. Thus, the objective of this study was to investigate the impact of S. virgaurea (SV) extract on the viability and ability to form biofilms of ESBL-Pseudomonas aeruginosa (P. aeruginosa). A cross-sectional study was conducted from August 2022 to March 2023. The broth microdilution method was employed to determine the minimum inhibitory concentration (MIC) of the (SV) extract. Subsequently, the minimum bactericidal concentration (MBC) was determined based on the MIC values obtained. The antibiotic susceptibility of bacteria was evaluated using the Kirby disk diffusion assay and an Antimicrobial Susceptibility Testing (AST) card in conjunction with the Vitek-2 compact system. Biofilm formation was evaluated using Congo red and a 96-well Elisa plate, while the presence of extended-spectrum β-lactamases (ESBLs) was estimated by measuring the reduction of nitrocefin at a wavelength of 390 nm. In addition, treatment of biofilm and ESBL activity with SV extract using 96-well Elisa plate and nitrocefin hydrolyzing, respectively. The resistance rates of P. aeruginosa isolates to the tested antibiotics were as follows: Levofloxacin 33%, Ciprofloxacin 40%, Amikacin 49%, Meropenem 50%, Cefepime 70%, Ceftazidime 75%, Cefotaxime 85%, Piperacillin-Tazobactam 90%, Amoxiclav 97%, Ampicillin 99%, Ceftriaxone 100%. The prevalence of MDR-P. aeruginosa, XDR-P. aeruginosa, PDR-P. aeruginosa and non-MDR-PA were 40% (n = 40), 7% (n = 7), 3% (n = 3) and 50% (n = 50), respectively. From the GC-MS results, it was observed that the presence of Octadecane, Clioquinol, Glycerol tricaprylate, hexadecanoic acid, cis-13-octadecenoic acid, oleic acid and Propanamide were the major components in the Solidago extract. In the determination of plant crude extracts, the values ranged between 0.25 and 64 mg/mL against bacteria. The resulting activity of the extract showed a significant statistical relationship at a p-value ≤ 0.01 against ESBL production and biofilm formation in P. aeruginosa. The S. virgaurea extract exhibited effectiveness in inhibiting biofilm formation and combating P. aeruginosa strains that produce extended-spectrum β-lactamases (ESBLs).
Keywords: Antimicrobial resistance; Biofilm; ESBLs; MDR; Pseudomonas aeruginosa; Solidago.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Antimicrobial and Anti-Biofilm Activities of Citrus sinensis and Moringa oleifera Against the Pathogenic Pseudomonas aeruginosa and Staphylococcus aureus.Cureus. 2020 Dec 28;12(12):e12337. doi: 10.7759/cureus.12337. Cureus. 2020. PMID: 33520533 Free PMC article.
-
Association Between Biofilm Formation Gene Bla exoU and Metallo and Extend Spectrum Beta-lactamase Production of Multidrug Resistance Pseudomonas aeruginosa in Clinical Samples.Comb Chem High Throughput Screen. 2022;25(7):1207-1218. doi: 10.2174/1386207324666210419112210. Comb Chem High Throughput Screen. 2022. PMID: 33874869
-
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).BMC Infect Dis. 2021 Jun 23;21(1):600. doi: 10.1186/s12879-021-06153-0. BMC Infect Dis. 2021. PMID: 34162341 Free PMC article.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Drugs. 2014. PMID: 24352909 Review.
Cited by
-
Biogenic Synthesis and Characterisation of Novel Potassium Nanoparticles by Capparis spinosa Flower Extract and Evaluation of Their Potential Antibacterial, Anti-biofilm and Antibiotic Development.Indian J Microbiol. 2024 Jun;64(2):548-557. doi: 10.1007/s12088-024-01190-0. Epub 2024 Feb 6. Indian J Microbiol. 2024. PMID: 39010993
References
-
- Al Maeni S.A.L., Ahmed M.M., Abed A.D., Abbas R.H., Jassim S.A.A., Mohamad A.M. Extraction and Purification of Staphylolysin Enzyme from Local Isolate of Pseudomonas aeruginosa. Ann. Rom. Soc. Cell Biol. 2021;25:1201–1208.
-
- Seder N., Rayyan W.A., Al-Fawares M.H.O., Bakar A. Pseudomonas aeruginosa Virulence Factors and Antivirulence mechanisms to Combat Drug Resistance; A Systematic Review. Mortality. 2023;10:11.
-
- Qin S., Xiao W., Zhou C., Pu Q., Deng X., Lan L., Liang H., Song X., Wu M. Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct. Target. Ther. 2022;7:199. doi: 10.1038/s41392-022-01056-1. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
